Endocrine Unit, Department of Medical Sciences, University of Milan, Milan, Italy.
Clin Endocrinol (Oxf). 2008 Feb;68(2):247-51. doi: 10.1111/j.1365-2265.2007.03029.x. Epub 2007 Sep 14.
Recombinant hGH (rhGH) therapy may unmask central hypoadrenalism in adults with organic GH deficiency (GHD), likely by normalizing 11beta-hydroxysteroid dehydrogenase type 1 isoenzyme (11betaHSD1) activity and reducing cortisone to cortisol conversion. The aim of the present study was to evaluate the hypothalamic-pituitary-adrenal (HPA) axis in children with idiopathic isolated GHD and normal pituitary magnetic resonance imaging (MRI) both before and during rhGH therapy.
This was a single-centre study of 10 consecutive children [five males and five females, mean age: 12.2 +/- 1.0 year]. Evaluation was performed at baseline and on rhGH (mean duration: 10.9 +/- 2.9 months, mean dose: 0.030 +/- 0.002 mg/kg bw/day).
HPA function was assessed by serum cortisol levels before and after appropriate provocative stimuli, that is, 1 microg ACTH test (N = 5 patients) or insulin tolerance test (ITT, N = 5 patients), evaluating all children with the same stimulation test both before and during rhGH therapy. Central hypoadrenalism was excluded by the presence of either a peak of > 500 nmol/l or a rise in cortisol levels of > 200 nmol/l, after both tests.
On rhGH therapy, serum IGF-I levels normalized, while serum cortisol and ACTH levels did not significantly differ from those recorded at baseline. The mean serum cortisol peak after both provocative tests was not significantly different on rhGH therapy and at baseline (498 +/- 41 vs. 580 +/- 35 nmol/l, respectively, P = 0.06), the mean cortisol rise being 280 +/- 45 and 270 +/- 36 nmol/l on rhGH and at baseline, respectively.
According to the diagnostic criteria, no child became hypoadrenal on rhGH, contrary to what observed in patients with organic GHD, further supporting the view that only in patients with organic multiple pituitary hormone deficiency GHD masks the presence of a hidden central hypoadrenalism.
重组人生长激素(rhGH)治疗可能通过使 11β-羟类固醇脱氢酶 1 同工酶(11βHSD1)活性正常化并减少皮质酮向皮质醇的转化,从而使患有器质性生长激素缺乏症(GHD)的成年人中的中枢性肾上腺功能减退症显现出来。本研究的目的是在 rhGH 治疗之前和期间评估特发性孤立性 GHD 且垂体磁共振成像(MRI)正常的儿童的下丘脑-垂体-肾上腺(HPA)轴。
这是一项单中心研究,纳入 10 例连续患者[男 5 例,女 5 例,平均年龄:12.2±1.0 岁]。在基线时和 rhGH 治疗时(平均持续时间:10.9±2.9 个月,平均剂量:0.030±0.002mg/kg bw/day)进行评估。
通过适当的刺激试验(即 1μg ACTH 试验[N=5 例]或胰岛素耐量试验[ITT,N=5 例])前后的血清皮质醇水平评估 HPA 功能,在 rhGH 治疗之前和期间对所有患儿均用相同的刺激试验进行评估。在两种试验之后,若皮质醇水平升高>200nmol/L,或峰值>500nmol/L,则排除中枢性肾上腺功能减退症。
rhGH 治疗后,血清 IGF-I 水平正常化,而血清皮质醇和 ACTH 水平与基线时相比无显著差异。rhGH 治疗和基线时的两种刺激试验后平均血清皮质醇峰值无显著差异(分别为 498±41 与 580±35nmol/L,P=0.06),皮质醇升高的平均值分别为 280±45 和 270±36nmol/L。
根据诊断标准,没有患儿在 rhGH 治疗期间出现肾上腺功能减退,这与有机 GHD 患者的观察结果相反,进一步支持了只有在患有器质性多种垂体激素缺乏症 GHD 的患者中,GHD 才会掩盖潜在的中枢性肾上腺功能减退症的观点。